Active and passive immunisation against respiratory syncytial virus

Area of Science:

• Immunology
• Vaccinology
• Pediatrics

Background:

• Respiratory Syncytial Virus (RSV) is a primary cause of respiratory illness in young children.
• Its impact on adults, the elderly, and immunocompromised individuals is increasingly recognized but often underestimated.
• A comprehensive understanding of age-specific immune responses to RSV is lacking, hindering effective intervention strategies.

Purpose of the Study:

• To review current strategies for developing RSV vaccines.
• To evaluate the efficacy and safety of existing and experimental RSV immunotherapies.
• To highlight the critical need for identifying immune correlates of protection for RSV vaccine development.

Main Methods:

• Literature review of RSV vaccine development strategies (live attenuated, subunit, peptide).
• Analysis of clinical data on RSV immunoprophylaxis (RSV-Ig) and monoclonal antibodies.
• Examination of challenges in understanding RSV immunology across different age groups.

Main Results:

• Various vaccine strategies show limited success; efficacy may vary by age group.
• RSV-Ig has demonstrated limited efficacy and safety concerns in specific infant populations.
• Humanized monoclonal antibodies show promise for passive immunotherapy but are still experimental.

Conclusions:

• Developing effective RSV vaccines requires a better understanding of human immune responses and correlates of protection.
• Current passive immunotherapies have limitations in efficacy, safety, and cost-effectiveness.
• Further research into novel vaccine platforms and targeted immunotherapies is essential for controlling RSV burden.